Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
Jennifer HammondCarla YunisRobert J FountaineGerald LuscanAimee M BurrWuyan ZhangWayne WisemandleHolly D SoaresMary Lynn BanieckiVictoria M HendrickVeselin KalfovRienk PypstraJames M RusnakPublished in: The New England journal of medicine (2024)
In this placebo-controlled trial, postexposure prophylaxis with nirmatrelvir-ritonavir for 5 or 10 days did not significantly reduce the risk of symptomatic SARS-CoV-2 infection. (Funded by Pfizer; ClinicalTrials.gov number, NCT05047601.).